Delivery Order SPE2DB22D6029-SPE2DB25FLVVB
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 26, 2025, for the supply of Zepbound 2.5 mg/0.5 mL pen injections with a contract ceiling value of $7,412.22 and an ultimate completion date of August 27, 2025. This non-set-aside, firm fixed-price delivery order represents a continuation of AmerisourceBergen's role as a critical pharmaceutical supplier to the federal government. The order will be fulfilled from the vendor's location in Conshohocken,...
- The Defense Logistics Agency awarded a $2,383.56 firm fixed price delivery order to AmerisourceBergen Drug Corp on July 14, 2025, for the supply of Zepbound 12.5 mg/0.5 mL pen injections. This non-competitive delivery order, with an ultimate completion date of July 15, 2025, represents a small-value pharmaceutical transaction supporting federal medical procurement needs. The award was fulfilled from AmerisourceBergen's place of performance in Conshohocken, Pennsylvania, where the company...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 5, 2025, for the supply of Zepbound 5 mg/0.5 mL pen injections, with a ceiling value of $1,143.87 and an ultimate completion date of September 8, 2025. This firm fixed-price, non-set-aside delivery order is performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The award represents a relatively modest transaction value, consistent with the company's role as a...
- The Defense Logistics Agency awarded a delivery order valued at $2,178.52 to AmerisourceBergen Drug Corp for Zepbound 10 mg/0.5 mL pen injections on June 24, 2025, with completion targeted for June 25, 2025. This competitively awarded, firm fixed-price delivery order represents fulfillment under AmerisourceBergen's broader pharmaceutical supply relationship with the federal government. The product will be delivered to the company's corporate office location in Conshohocken, Pennsylvania. This...
- The Defense Logistics Agency awarded a delivery order valued at $1,525.20 to AmerisourceBergen Drug Corp for the supply of Zepbound 12.5 mg/0.5 ml pen injections on July 24, 2025. This firm fixed-price, competitively awarded contract is classified as a delivery order with no set-aside designation and carries an ultimate completion date of July 25, 2025. The pharmaceutical product will be performed from AmerisourceBergen's location in Conshohocken, Pennsylvania, the company's corporate...
- The Defense Logistics Agency awarded a $13,372.43 firm fixed price delivery order to AmerisourceBergen Drug Corp on September 3, 2025, for the supply of Zepbound 5 mg/0.5 ml pen injections. The contract, which is set to be completed by September 4, 2025, will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order was awarded competitively without a set-aside designation, reflecting the contractor's demonstrated capability to meet...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 29, 2025, for the supply of Zepbound 12.5 mg/0.5 ml pen injections with a ceiling value of $3,648.19. This firm fixed-price delivery order is set to be completed by July 30, 2025, and will be performed at AmerisourceBergen's facility in Conshohocken, Pennsylvania. The contract was competitively awarded without set-aside designation and represents a routine pharmaceutical supply transaction under the...
- The Defense Logistics Agency awarded a delivery order valued at $9,927.33 to AmerisourceBergen Drug Corp for the supply of Zepbound 5 mg/0.5 ml pen injectors on April 24, 2025, with completion scheduled for April 25, 2025. This firm fixed-price, competitively awarded delivery order represents a continuation of AmerisourceBergen's substantial role as a critical pharmaceutical supplier to the federal government. The order will be fulfilled from the contractor's location in Conshohocken,...
- The Defense Logistics Agency awarded a delivery order valued at $12,661.98 to AmerisourceBergen Drug Corp for the supply of Zepbound 15 mg/0.5 mL pen injections on August 25, 2025, with completion scheduled for August 26, 2025. This firm fixed-price delivery order, which was competitively awarded without set-aside restrictions, represents a continuation of the vendor's critical role in federal pharmaceutical procurement. The order will be fulfilled from AmerisourceBergen's location in...
- The Defense Logistics Agency awarded a delivery order valued at $1,096.88 to AmerisourceBergen Drug Corp for the supply of Zepbound 7.5 mg/0.5 ml pen injections on August 14, 2025. The contract is classified as firm fixed price with an ultimate completion date of August 15, 2025, and will be performed at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. This delivery order was competitively awarded with no set-aside designation, reflecting the company's capability to meet...
- SPE2DB22D6029Indefinite Delivery Contract
- SPE2DB22D6029-SPE2DB25FLVVBDelivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 3, 2025, for the supply of Zepbound 12.5 mg/0.5 ml pen injections with a ceiling value of $1,525.16. This is a firm fixed price delivery order with an ultimate completion date of September 4, 2025, and represents a non-set-aside competitive award. The work will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, which serves as the company's headquarters and a critical hub for its federal pharmaceutical distribution operations. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999.99 billion prime vendor agreement that runs through December 2026 and provides comprehensive global pharmaceutical support to military healthcare programs worldwide. AmerisourceBergen is a major pharmaceutical distributor serving as a critical vendor for federal medical procurement, particularly supporting the Defense Health Agency and other government healthcare systems. The company's federal contract portfolio demonstrates extensive experience supplying a broad range of pharmaceutical products including specialty medications, brand-name and generic drugs, vaccines, and medical supplies across multiple therapeutic domains.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.5k | 9/3/25 |